Liraglutide for weight loss in obese people.
Pär
P
Hallberg
Sofie
S
Schwan
Håkan
H
Melhus
D019440:Anti-Obesity Agents / Q000009:adverse effects*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D054795:Incretins / Q000009:adverse effects*; D000069450:Liraglutide; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009765:Obesity / Q000188:drug therapy*; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced; D015431:Weight Loss / Q000187:drug effects*
D019440:Anti-Obesity Agents; D054795:Incretins; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1